

In the News: Congratulations to the following awardees!!



Saptarshi Chakraborty, Assistant Professor of Biostatistics, is Co-I on a continuation award from the National Institute of Biomedical Imaging and Bioengineering/NIH (PI: Jun Xia, Biomedical Engineering) for the project entitled, *Multiparametric Photoacoustic and Ultrasonic Imaging of the Breast in Cranial-caudal View*. The project will develop a three-dimensional (3D) breast screening system using integrated photoacoustic and ultrasound imaging techniques to address the unmet clinical need in breast cancer screening for women with high breast density.



Rachael Hageman Blair, Associate Professor of Biostatistics, is PI on a new award from the University of Western Australia/NIH for the project entitled, *Emotion Regulation in Distress Disorders: Elucidating the Role of Cognitive Processes and Person-Situation Fit in the Laboratory and Daily Life*. The study will examine predictors (i.e., emotional awareness, contextual sensitivity, perseverative negative thinking) of dysfunctional emotion regulation that contribute to depression and anxiety, as well as to provide an initial framework for optimal emotion regulation in individualized daily life contexts.



David Hostler, Professor and Chair of Exercise and Nutrition Sciences, is PI on a new award from the US Navy Office of Naval Research, for the project entitled, *DURIP: CRESE Annular Pool Refurbishment*. The awards provides funding for restoration of the large annular pool, the only one of its kind in the world and a critical piece of infrastructure to support diving and undersea research for the Navy and DOD.



Michael LaMonte, Research Professor, is MPI on a new award from University of California at San Diego/NIH for the project entitled, *Objective Physical Activity and Cardiovascular Health in Older Women: OPACH2*. The study will build on the success of OPACH1 and further characterize the type, amount, and intensity of physical activity (PA) needed to maintain cardiovascular health in older adults. The findings could lead to transformed and refined guidelines by conveying accurate and realistic PA goals for older Americans.



Elizabeth Mietlicki-Baase, Assistant Professor of Exercise and Nutrition Sciences, is PI on a new award from the Foundation for Prader-Willi Research (FPWR) for the project entitled, *PWS Reagent Sharing Grant*. Dr. Mietlicki-Baase's lab has been working with FPWR's novel MAGEL2-deficient rat to investigate aspects of energy balance control. This award provides funding for Dr. Mietlicki-Baase to breed and genotype this rat model to share with another lab, who will perform complementary studies and provide further insight into the metabolic phenotype of this rodent model.



Kimberly Naus, Director of CAT Client Services, received a renewal award from the NYS Office of Children and Family Services for the project entitled, *OCFS Assistive Technology Center*. The award provides funding for assistive technology services to eligible participants whose vocational rehabilitation goal requires expertise in the use of adaptive electronic technologies during post-secondary education or training or during employment.



Ms. Naus and Erin Brunelle, Occupational Therapist with CAT, also received three renewals from the NYS Justice Center for the Protection of People with Special Needs for the projects

entitled, *Technology-Related Assistance for Individuals with Disabilities (TRAID) Program; TRAIID Program – Money Follows People*; and *TRAID Program – ACCES/VR*. The TRAIID Programs seek to increase awareness of, use, and implementation of assistive technology (AT) and provide information and referrals to improve the function, participation, and independence of individuals of all ages with disabilities.



Kirkwood Personius, Clinical Associate Professor of Rehabilitation Science received a continuation award from the National Institute of Allergy and Infectious Diseases/NIH (PI: Elizabeth Wohlfert, Microbiology & Immunology) for the project entitled, *T Regulatory Cell Responses in Toxoplasma-infected Muscle*. The goal of the study is to understand how regulatory T cells can be manipulated in the context of chronic infection.



Todd Rideout, Associate Professor of Exercise and Nutrition Science is PI on a continuation award from the National Center for Complementary & Integrative Health/NIH for the research project entitled, *Alpha Lipoic Acid as a Maternal Supplement in Obese Pregnancies*. The study is exploring dietary supplementation of α -lipoic acid as a means to protect against maladaptive programming of obesity in offspring.



Ahmed Soliman, Predoctoral Student in Epidemiology and Environmental Health, received a new fellowship award from the American Heart Association, Inc. for the project entitled, *Proton Pump Inhibitors and Measures of Cardiovascular Health in Postmenopausal Women*. The study will examine the association between the use of proton pump inhibitors and new cardiovascular events in those with no history of heart disease. **Michael LaMonte**, Research Professor of EEH, serves as faculty sponsor.



Congratulations to all the SPHHP Faculty who were awarded new grants (as PI or Co-I) from the University at Buffalo's 2023 CTSI Pilot Studies Program:



Ekaterina Noyes, PI, Katherine Amato and Heather Orom, Co-Is, for the project entitled, *Video-Based Educational Approach to Increase Cancer Screening Amongst People of Color and Low Health Literacy Populations*.



Riana Pryor, PI, and David Hostler, Co-I, for the project entitled, *Biomarkers to Assess Acute Kidney Injury Risk During Heat Strain*.



Ghazala Saleem, PI, and Jacob McPherson, Co-I, for the project entitled, *Assessing the Efficacy of Alterations in Subcortical-Cortical Functioning Connectivity from Transcranial Direct Current Stimulation in Older Children After Mild Traumatic Brain Injury*.



Gregory Wilding is Co-I on the following awards:

Effect of Low-Dose Lithium Therapy on Long COVID Symptoms: A Randomized Controlled Trial. (PI: Thomas Guttuso, Neurology)

Evaluating the Social Workers Addressing Firearm Risk (SAFR) Intervention: A Pilot Study (PI: Patricia Logan-Greene, Social Work)

A Family-Based Approach to Treat Overweight and Its Co-Morbidities in Youth with Type 1 Diabetes and Their Parents (PI: Teresa Quattrin, Pediatrics)

In This Issue

In the News: Congratulations to the Following Awardees	1
Grant Clinic	3
NIH Funding Opportunities	
Request for Applications (RFA)	5
Program Announcements Reviews in an Institute (PARs)	9
Program Announcement (PA).....	12
Words to Live By	12

Grant Clinic

GENERAL NOTICE

[NOT-OD-23-045](#)

Publication of the Revised NIH Grants Policy Statement (Rev. December 2022) for Fiscal Year 2023

The NIH announces publication of the updated NIH Grants Policy Statement (NIHGPS, rev. December 2022). The NIHGPS provides both up-to-date policy guidance that serves as NIH standard terms and conditions of award for all NIH grants and cooperative agreements, and extensive guidance to those who are interested in pursuing NIH grants. This update is applicable to all NIH grants and cooperative agreements with budget periods beginning on or after October 1, 2022. The current version of the NIHGPS, in both HTML and PDF formats, as well as previous versions of the NIHGPS and documents summarizing significant changes implemented with each revision, are available on the [NIH Grants Policy](#) website.

[NOT-OD-23-047](#)

Updates to the Non-Discrimination Legal Requirements for NIH Recipients

Promoting equity is essential to NIH's mission of seeking fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. This view is reflected in Executive Order (E.O.) 13985 entitled Advancing Racial Equity and Support for Underserved Communities Through the Federal Government (Jan. 20, 2021). Please refer to notice for updated language that has been applied to all active NIH NOFOs and NOFOs issued on or after the date of this notice on December 23, 2022

[NOT-HS-23-006](#)

AHRQ Announces Interest in Research on Climate Change and Healthcare

Climate change is the leading threat to public health, contributing to both individual health problems and broader disruptions to vital infrastructure and the healthcare system. This Special Emphasis Notice (SEN) announces AHRQ's interest in receiving health services research grant applications that address the intersection of climate change and healthcare. For additional information, please click the link to the Notice.

[NOT-HS-23-007](#)

Notice of Intent to Publish funding Opportunity Announcement to Support the Management of Substance Use Disorders in Primary Care and other Ambulatory Settings (R18)

AHRQ intends to publish a NOFO announcement using the R18 mechanism to support projects that develop and test strategies to improve the capacity of primary care and ambulatory settings to provide evidence-based, patient-centered care for people who misuse opioids and other substances.

[NOT-AA-23-001](#)

Notice of Guidance for Data Management and Sharing Plans for the National Institute of Alcohol Abuse and Alcoholism (NIAAA)

The purpose of this notice is to inform the extramural research community that NIAAA expects specific

information in the Data Management and Sharing Plan (DMS Plan) to be included in NIAAA grant applications for due dates on or after January 25, 2023. These instructions will be included in all NIAAA Funding Opportunity Announcements going forward. In addition to the general NIH guidance regarding the information to include in the DMS Plan (NOT-OD-21-014, Supplemental Information to the NIH Policy for Data Management and Sharing: Elements of an NIH Data Management and Sharing Plan, and the NIH Data Management and Sharing Plan format page), NIAAA expects that the DMS Plan elements contain specific information. Please click the link to the Notice for additional information.

[NOT-AA-23-002](#)

Notice of NIAAA Data-Sharing Information for Human Subjects Grants Research Funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) [5th Revision]

The purpose of this Notice is to revise and replace the current NIAAA language for Data Sharing requirements (NOT-AA-22-011), to align with the NIH Policy for Data Management and Sharing (NOT-OD-21-013). This Notice applies to all grant applications and awards that involve human subject research for due dates on or after January 25, 2023 and applies to all Funding Opportunity Announcements (FOAs) in which NIAAA participates. Applications submitted to or assigned to NIAAA on or after January 25, 2023 must follow the Final NIH Policy for Data Management and Sharing (NOT-OD-21-013) and provide a Data Management and Sharing (DMS) Plan. For grants involving human subject data, NIAAA expects the data to be submitted to the NIAAA-sponsored data repository, the NIAAA Data Archive (NIAAADA), as outlined in this Notice. These instructions will be included in all NIAAA FOAs going forward. Please click on the link to the Notice for detailed information.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-CA-23-018](#) – **Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer**

This NOSI is to solicit applications directed toward identifying, characterizing, and mitigating risk factors, identifying biomarkers for early detection, best screening modalities, and preventive interventions for early-onset colorectal cancer (EOCRC), defined as occurring before 50 years of age. This Notice applies to due dates on or after **February 5, 2023**, and subsequent receipt dates through **September 7, 2024**.

[NOT-DA-22-048](#) – **Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases**

This NOSI encourages studies of the endocannabinoid system (ECS) and its roles in brain health and acute and chronic disease, substance use, and substance use disorder (SUD). The desired outcomes of research will be a mechanistic understanding of how cannabinoids and manipulation of the ECS can elicit both therapeutic and deleterious effects as well as the role of cannabinoids and ECS in symptom management. This Notice applies to due dates on or after **February 5, 2023**, and subsequent receipt dates through **January 7, 2026**.

[NOT-LM-23-001](#) – **Computational and Statistical Methods to Enhance Discovery from Health Data**

The National Library of Medicine is issuing this Notice to highlight its interest in receiving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets. This Notice applies to due dates on or after **February 5, 2023**, and subsequent receipt dates through **January 8, 2026**.

[NOT-OD-23-039](#) – **Firearm Injury and Mortality Prevention Research**

The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality. This Notice applies to due dates on or after **February 5, 2023**, and subsequent receipt dates through **February 5, 2026**.

[NOT-MH-23-140](#) – Priority Research Opportunities in Crisis Response Services

NIMH, NIDA, and ORWH are issuing this NOSI to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. This Notice applies to due dates on or after **February 5, 2023**, and subsequent receipt dates through **May 8, 2025**.

[NOT-CA-23-035](#) – Career Development Opportunities for Research Within the Mission of the Division of Cancer Prevention at the National Cancer Institute

This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from early career scientists conducting research within the mission of the Division of Cancer Prevention. This Notice applies to due dates on or after **February 12, 2023**, and subsequent receipt dates through **November 12, 2024**.

[NOT-OD-23-040](#) – Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21)

The purpose of this Notice of Special Interest (NOSI) is to support secondary data analysis to address questions and advance scientific inquiry related to SARS-CoV-2 through the existing data resources in the Rapid Acceleration of Diagnostics Data Hub ([RADx DataHub](#)), including and in conjunction with other data resources. This Notice applies to due dates on or after **February 16, 2023**, and subsequent receipt dates through **May 30, 2023**.

[NOT-CA-23-037](#) – Technology Development for Cancer Control and Population Science Research

The purpose of this Notice is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field. This Notice applies to due dates on or after **March 1, 2023**, and subsequent receipt dates through **December 31, 2024**.

[NOT-DA-24-001](#) – Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine

NIDA is interested in receiving research proposals focusing on studying pharmacogenomics in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse. This Notice applies to due dates on or after **June 5, 2023**, and subsequent receipt dates through **May 8, 2026**.

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

APRIL 2023 DUE DATES

[RFA-OD-23-003](#) – (R25 Independent Clinical Trial Not Allowed)

Short Courses on Innovative methodologies and Approaches in the Behavioral and Social Sciences

This RFA is to support courses for skills development in cross-cutting methodologies and analytics that are needed to advance behavioral and social sciences research (BSSR) but are not well-addressed by existing educational programs widely available to the BSSR community. **Application Due Date:** April 17, 2023

MAY 2023 DUE DATES

[RFA-ES-23-002](#) – (R24 Clinical Trial Not Allowed)

Accelerating Data and Metadata Standards in the Environmental Health Sciences

The purpose of this Funding Opportunity Announcement (FOA) is to support resource projects to enable Environmental Health Sciences (EHS) communities to openly develop, extend, adapt, or refine data and metadata standards as well as associated tools to implement standards. The initiative is intended to catalyze community-driven standards development and related implementation in environmental health. **Application Due Date:** May 10, 2023

AUGUST 2023 DUE DATES

[RFA-DA-24-013](#) – (R01 Clinical Trials Not Allowed)

[RFA-DA-24-014](#) – (R21 Clinical Trials Not Allowed)

Mechanisms and Targets at the Intersection of HIV and Substance Use

The purpose of this FOA is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. *Letter of Intent due date – July 9, 2023. Application Due Date:* August 9, 2023

MULTIPLE DUE DATES

[RFA-CA-22-050](#) (R01 Clinical Trial Optional)

NCI Cancer Moonshot Scholars Diversity Program (CMSDP)

The NCI, in alignment with NIH, continues to demonstrate a strong commitment to attracting, training, and retaining the best minds from diverse backgrounds to ensure long-term successes in the cancer research enterprise. The overarching goal of the CMSDP is to increase the number of R01 Early-Stage Investigators and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups ([NOT-OD-20-031](#), Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply.

Application Due Dates: June 6, 2023, February 6, 2024

[RFA-CA-23-014](#) – (R21 Clinical Trial Optional)

Development of Innovation Informatics Methods and Algorithms for Cancer Research and Management

The importance of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation and that have the potential to accelerate or enhance cancer research by inviting Exploratory/Developmental Research grant applications for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum. **Application Due Dates:** June 13, 2023, November 17, 2023

[RFA-CA-23-015](#) – (U01 Clinical Trial Optional)

Early-Stage Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on early-stage development, defined here as initial tool development or the significant modification of an existing tool for a new cancer research application. The FOA encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research.

Application Due Dates: June 13, 2023, November 17, 2023

[RFA-CA-23-016](#) – (U24 Clinical Trial Optional)

Advanced Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. **Application Due Dates:** June 13, 2023, November 17, 2023

[RFA-CA-23-017](#) – (U24 Clinical Trial Optional)

Sustained Support for Informatics Technologies for Cancer Research and Management

The purpose of this Announcement is to invite Cooperative Agreement applications for the continued development and sustainment of high-value informatics research resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Dates:** June 13, 2023, November 17, 2023

[RFA-HL-23-018](#) (R21)

Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the

available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at www.biolincc.nih.gov.

Application Due Dates: June 20, 2023; October 19, 2023, June 20, 2024; and October 21, 2024.

[RFA-HL-22-010](#) (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) (K01 Independent Clinical Trial Not Allowed)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: October 13, 2023, February 13, 2024

[RFA-OD-22-023](#) – (K01 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-024](#) – (K01 – Independent Clinical Trial Required)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research is to provide support and protected time for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Due Dates:** November 14, 2023, July 12, 2024, March 12, 2025

[RFA-OD-22-025](#) – (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-026](#) – (K99/R00 – Independent Clinical Trial Required)

Pathway to Independence Award in Tobacco Regulatory Research

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. **Application Due Dates:** November 14, 2023, July 12, 2024, March 12, 2025

[RFA-DA-23-013](#) (R01 Clinical Trial Optional)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes through Community-engaged Research

This FOA seeks to fund innovative community partnered research by diverse teams that addresses community-driven priorities for reducing disparities in outcomes for racial and ethnic minority populations related to in substance use, addiction, and related health outcomes consequences, including HIV.

Application Due Dates: November 14, 2023, November 14, 2024

[RFA-DA-23-061](#) (R01 Clinical Trial Optional)

[RFA-DA-23-062](#) (R34 Clinical Trial Optional)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations

The purpose of this FOA is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-026](#) (DP1 Clinical Trial Optional)

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity

This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. This award supports transformative, boundary-pushing applications that may be risky or at a stage too early to fare well in the traditional peer review process. **Applications Due Dates:** November 14, 2023 and November 14, 2024

[RFA-DA-23-028](#) (R61/R33 Clinical Trial Optional)

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory

This funding announcement invites exploratory mechanistic research seeking to parse the complex effects of structural racism and investigate its impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. **Application Due Dates:** November 14, 2023; November 14, 2024

[RFA-DA-23-053](#) (R61/R33 Clinical Trial Optional)

[RFA-DA-23-054](#) (R33 Clinical Trial Optional)

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis

This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. **Application Due Dates:** November 15, 2023; March 20, 2024

[RFA-OD-22-028](#) (R01 Clinical Trial Optional)

The Intersection of Sex and Gender Influences on Health and Disease

The purpose of this FOA is to invite applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#). **Application Due Dates:** November 22, 2023; November 22, 2024

[RFA-HL-23-004](#) (R35, Clinical Trial Optional)

NHLBI Outstanding Investigator Award (OIA)

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. **Application Due Date:** February 15, 2024

[RFA-HL-23-005](#) (R35, Clinical Trial Optional)

NHLBI Emerging Investigator Award (EIA)

The purpose of this award is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. **Application Due Date:** February 15, 2024

[RFA-DA-22-037](#) (R01, Clinical Trial Optional)

[RFA-DA-22-038](#) (R21, Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. **Application Receipt Dates:** Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-22-040](#) (R01, Clinical Trial Optional)

High Priority HIV and Substance Use Research

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-CA-22-045](#) (R35 Clinical Trial Optional)

NCI Outstanding Investigator Award

The Outstanding Investigator Award is based on the accomplishments of the applicant. It is meant to support the cancer research program of individual scientists of exceptional creativity, demonstrated outstanding research accomplishments, and seminal past contributions in cancer research. For this FOA, the research strategy is expected to evolve over the seven-year award period. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 8, 2024

[RFA-DA-23-008](#) (R61/R33, Clinical Trial Required)

Stimulants and HIV: Addressing Contemporary and Recurring Epidemics

The primary goal of this FOA is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 13, 2024

[RFA-DA-23-021](#) (R43/R44, Clinical Trial Optional)

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)

This FOA encourages SBIR grant applications directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 15, 2025

[RFA-NS-22-022](#) – (K99/R00 Independent Clinical Trial Not Allowed)

[RFA-NS-22-023](#) – (Independent Basis Experimental Studies with Humans Required)

HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAID and SUD Research

The purpose of this Announcement is to assist eligible postdoctoral researchers in research areas supported by the NIH HEAL Initiative®, with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. Applications appropriate for this FOA may propose biomedical research across the spectrum of Pain and SUD research areas. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025

[RFA-NS-22-024](#) – (K99/R00 Independent Basic Experimental Studies with Humans Required)

[RFA-NS-22-025](#) – (K99/R00 Independent Clinical Trial Not Allowed)

HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity

The purpose of this FOA is to assist a cohort of new and talented independent investigators from diverse backgrounds (e.g. see [NOT-OD-20-031](#) Notice of NIH's Interest in Diversity) with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. Applications appropriate for this FOA may propose biomedical research across the spectrum of Pain and SUD research areas. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025

[RFA-ES-23-004](#) – (R21 Clinical Trial Not Allowed)

Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA is intended to support research in environmental health science in which an event has or will imminently occur that provides a limited window of opportunity to collect samples and data to support the assessment of exposures and human health impact. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 2, 2025

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-23-083](#) – (R61 Clinical Trial Optional)

Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline

This FOA invites research grant applications that enable the collection of *pilot data* to support early stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. The goal of these pilot data is to serve as

preliminary data for applications to the early stage and late stage clinical trial [PAR-23-081](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 19, 2024.

[PAR-23-081](#) – (R01 Clinical Trial Optional)

Early and Late-Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline

This FOA invites research grant applications that enable the early- to late-stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/DRD across the spectrum from pre-symptomatic to more severe stages of disease. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2025

[PAR-23-055](#) – (R01 Clinical Trial Not Allowed)

[PAR-23-056](#) – (R21 Clinical Trial Not Allowed)

Co-infection and Cancer

This FOA is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** R01 – October 5, 2025; R21 – October 16, 2025

[PAR-23-072](#) – (R13 Clinical Trial Not Allowed)

FDA Support for Conferences and Scientific Meetings

The purpose of the FDA Scientific Conference Grant Program is to facilitate the provision of federal financial assistance in support of high-quality conferences and scientific meetings designed to research and investigate a topic clearly aligned with the FDA mission. *A Letter of Intent requesting advanced permission to submit a conference application is required and must be received via e-mail no later than eight (8) weeks prior to the selected application due date.* **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** October 11, 2025

[PAR-23-051](#) – (U01 Clinical Trial Not Allowed)

[PAR-23-052](#) – (UH2 Clinical Trial Not Allowed)

Mechanistic links between diet, lipid metabolism, and tumor growth and progression

The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** October 24, 2025

[PAR-23-076](#) – P50 Clinical Trial Optional)

NIDA Research Center of Excellence Grant Program

This FOA is to provide support for research Centers that (1) conduct substance use and addiction research in any area of NIDA’s mission, including the intersection of substance use/addiction and HIV, (2) foster outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to relevant research communities, educational organizations, the general public, and policy makers. **Application Due Dates:** Multiple dates; see announcement. **Expiration Date:** November 19, 2025

[PAR-23-053](#) – (R61/R33 – Clinical Trial Optional)

Research Infrastructure Development for Interdisciplinary Aging Studies

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. Applications should propose the development of research infrastructure to advance specific topics in aging science that require interdisciplinary partnerships or collaborations. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 3, 2025

[PAR-23-058](#) – (R03 Clinical Trial Optional)

NCI Small Grants Program for cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus)

This funding opportunity supports small research projects on cancer that can be carried out in a short period of time with limited resources. This grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-034](#) – (R01 Clinical Trial Optional)

NLM Research Grants in Biomedical Informatics and Data Science

This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-036](#) – (R21 Clinical Trial Not Allowed)

Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders

This FOA encourages applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-057](#) – (R01 Clinical Trial Required)

NIA Multi-site Clinical Trial Implementation Grant

This FOA invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the [NIA website](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-064](#) – (P01 Clinical Trial Optional)

NIDA Program Project Grant Applications

NIDA seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, medications development, health services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) and associated consequences in people who use or misuse substances or have a substance use disorder, or other research areas relevant to substance use, misuse, or use disorders. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-112](#) – (R01 – Clinical Trial Optional)

Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities

This initiative will support intervention research that addresses structural racism and discrimination (SRD) in order to improve minority health or reduce health disparities. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-060](#) – (R34 Clinical Trial Optional)

Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes

[PAR-23-061](#) – (R21 Clinical Trial Optional)

[PAR-23-062](#) – (R01 Clinical Trial Optional)

Innovations to Optimize HIV Prevention and Care Continuum Outcomes

The NIMH invites applications for Research Project Grants that propose formative research, intervention development, and pilot-testing of interventions; formative implementation research to inform adaptation of evidence-based interventions; or development or selection of implementation strategies. Primary scientific areas of focus include the feasibility, acceptability, and safety of novel or adapted interventions that target HIV prevention or treatment, or implementation outcomes using implementation science approaches. Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-

scale clinical trials or implementation science approaches should consider using the companion R01 mechanism, PAR-23-062. If proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models, applications should consider the R21 mechanism (PAR-23-061). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 10, 2026

[PAR-23-077](#) – (RM1 – Clinical Trial Optional)

Collaborative Program Grant for Multidisciplinary Teams

This Announcement encourages Collaborative Program Grant applications from institutions/organizations that propose projects addressing complex and challenging biomedical problems within the mission of NIGMS. **Application Due Dates:** Multiple Dates, see announcement. **Expiration Date:** January 28, 2026

[PAR-23-037](#) – (U01 Clinical Trial Optional)

Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities

The purpose of this FOA is to invite applications for multisite clinical trials and large-scale observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice [NOT-HD-19-034](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-111](#) – (R21 – Clinical Trial Optional)

NIMHD Exploratory/Developmental Research Grant Program

NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-23-048](#)

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32)

Expiration Date: May 8, 2026

[PA-23-080](#)

Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35)

Expiration Date: May 8, 2026

[PA-23-115](#)

AHRQ Small Research Project to Advance the Science of Primary Care (R03)

Expiration Date: March 19, 2027

Words to Live By

"Life is like a camera. Just focus on what's important, capture the good times, develop from the negatives, and if things don't turn out - take another shot."

-- Author Unknown

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras